- Home
- ATHA vs DWTX Comparison
ATHA vs DWTX Comparison
Compare ATHA & DWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- DWTX
- Stock Information
- Founded
- ATHA 2011
- DWTX 2012
- Country
- ATHA United States
- DWTX United States
- Employees
- ATHA N/A
- DWTX N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- DWTX
- Sector
- ATHA Health Care
- DWTX
- Exchange
- ATHA Nasdaq
- DWTX NYSE
- Market Cap
- ATHA 21.0M
- DWTX 20.1M
- IPO Year
- ATHA 2020
- DWTX N/A
- Fundamental
- Price
- ATHA $0.43
- DWTX $5.36
- Analyst Decision
- ATHA Buy
- DWTX
- Analyst Count
- ATHA 4
- DWTX 0
- Target Price
- ATHA $11.25
- DWTX N/A
- AVG Volume (30 Days)
- ATHA 210.5K
- DWTX 1.5M
- Earning Date
- ATHA 03-04-2025
- DWTX 03-04-2025
- Dividend Yield
- ATHA N/A
- DWTX N/A
- EPS Growth
- ATHA N/A
- DWTX N/A
- EPS
- ATHA N/A
- DWTX N/A
- Revenue
- ATHA N/A
- DWTX N/A
- Revenue This Year
- ATHA N/A
- DWTX N/A
- Revenue Next Year
- ATHA N/A
- DWTX N/A
- P/E Ratio
- ATHA N/A
- DWTX N/A
- Revenue Growth
- ATHA N/A
- DWTX N/A
- 52 Week Low
- ATHA $0.41
- DWTX $1.62
- 52 Week High
- ATHA $4.21
- DWTX $29.28
- Technical
- Relative Strength Index (RSI)
- ATHA 34.62
- DWTX N/A
- Support Level
- ATHA $0.42
- DWTX N/A
- Resistance Level
- ATHA $0.46
- DWTX N/A
- Average True Range (ATR)
- ATHA 0.04
- DWTX 0.00
- MACD
- ATHA -0.00
- DWTX 0.00
- Stochastic Oscillator
- ATHA 10.85
- DWTX 0.00
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.